Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study
- 1 January 2003
- journal article
- clinical trial
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 19 (5) , 383-394
- https://doi.org/10.1185/030079903125002009
Abstract
SUMMARYObjective: To compare the effects of alendronate (ALN) 70mg once weekly (OW) and risedronate (RIS) 5mg daily between-meal dosing on biochemical markers of bone turnover and bone mineral density (BMD) in postmenopausal women with osteoporosis.Research design and methods: This was a 3-month, randomised, double-blind, placebo-controlled study with a double-blind extension to 12 months. The study enrolled 549 postmenopausal women (ALN 219, RIS 222 and placebo (PBO) 108) who were >60 years of age at outpatient centres.Main outcome measures: The primary endpoint was reduction in urine N-telopeptides of type 1 collagen (NTx) corrected for creatinine level at 3 months. Secondary parameters included change in BMD at the spine and hip at 6 and 12 months, NTx at 1,6 and 12 months, and serum bone-specific alkaline phosphatase (BSAP) at 1, 3, 6 and 12 months. Adverse experiences (AEs) were recorded throughout the study for an assessment of treatment safety profiles and tolerability.Results: Over 3 months, ALN p...Keywords
This publication has 34 references indexed in Scilit:
- Two-Year Results of Once-Weekly Administration of Alendronate 70 mg for the Treatment of Postmenopausal OsteoporosisJournal of Bone and Mineral Research, 2002
- Tolerability of Once-Weekly Alendronate in Patients With Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled StudyMayo Clinic Proceedings, 2002
- Alendronate Reduces the Risk of Multiple Symptomatic Fractures: Results from the Fracture Intervention TrialJournal of the American Geriatrics Society, 2002
- Association of prevalent vertebral fractures, bone density, and alendronate treatment with incident vertebral fractures: effect of number and spinal location of fracturesBone, 1999
- The effect of dosing regimen on the pharmacokinetics of risedronateBritish Journal of Clinical Pharmacology, 1999
- Alendronate Increases Bone Density and Bone Strength at the Distal Radius in Postmenopausal WomenJournal of Bone and Mineral Research, 1999
- Early Changes in Biochemical Markers of Bone Turnover Predict the Long-Term Response to Alendronate Therapy in Representative Elderly Women: A Randomized Clinical TrialJournal of Bone and Mineral Research, 1998
- Increased bone turnover in late postmenopausal women is a major determinant of osteoporosisJournal of Bone and Mineral Research, 1996
- The worldwide problem of osteoporosis: Insights afforded by epidemiologyBone, 1995
- Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosisJournal of Bone and Mineral Research, 1994